SLICE® is an aquaculture premix containing emamectin benzoate and is only available through Merck Animal Health. SLICE® premix can be purchased through Merck Animal Health and sent to an aquaculture feed mill for top coating. The primary goal of field studies conducted under INAD #11-370 is to evaluate the efficacy of SLICE®-medicated feed and safety of SLICE® to control mortality caused by external parasites in a variety of freshwater and marine fish species. The treatment option that is allowed to administer SLICE® in feed is 50 µg EB per kg of fish biomass per day for 7 consecutive days, and the investigational withdrawal period for treated fish is 60 days. Note: SLICE doesn’t usually reach fully efficacy until 25-35 days after treatment depending on water temperature. This INAD requires all participants to be approved by the FDA Environmental Team prior to participation – this review will take 90 days. To participate in the INAD Program for SLICE® visit the data collecting site.
Please read the Study Protocol prior to any treatments. It contains the protocol, MSDS, and a copy of the forms to be used as a guide for collecting data that will be entered into the online INAD database. The FDA authorization letter(s) for this INAD is currently only available by emailing Bonnie Johnson.
INAD objective/purpose: Collect scientific data necessary to establish the effectiveness AND safety of SLICE® to control mortality caused by external parasites in a variety of freshwater fish species.
SLICE® (emamectin benzoate; 0.2% aquaculture premix)
Merck Animal Health
35500 W. 91st Street
De Soto, KS 66018
Kasha M. Cox
Target pathogen(s): parasitic copepods
Method of administration: Medicated feed treatment
Investigational Withdrawal period:
Required test parameters:
Limitations or restrictions on use of drug:
Required INAD fee: $700/facility/year
AADAP Contact Information:
Ms. Bonnie Johnson, FWS-AADAP